Infliximab therapy decreases the levels of TNF-α and IFN-γ mRNA in colonic mucosa of ulcerative colitis

References

• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390–407
   PubMedGoogle Scholar
• Dionne S, Hiscott J, D'Agata I, Duhaime A, Seidman EG. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997; 42: 1557–66
   PubMed Web of Science ®Google Scholar
• Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004; 19: 308–15
   PubMedGoogle Scholar
• McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001; 50: 491–5
   PubMed Web of Science ®Google Scholar
• Melmed GY, Abreu MT. New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep 2004; 6: 474–81
   PubMedGoogle Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521–33
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M, Klein JS, de la MC, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261–70
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550–64
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, et al. Tissue levels of tumor necrosis factor-alpha correlate with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007; 42: 1312–20
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805–11
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van AG, Vermeire S. Infliximab therapy for inflammatory bowel disease: seven years on [review article]. Aliment Pharmacol Ther 2006; 23: 451–63
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244–79
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251–9
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323–32
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774–85
   PubMed Web of Science ®Google Scholar
• Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhances the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 353–66
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128: 376–92
   PubMed Web of Science ®Google Scholar
• Ten HT, van MC, Peppelenbosch MP, Van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206–11
   PubMed Web of Science ®Google Scholar
• Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145–57
   PubMed Web of Science ®Google Scholar
• Hassan C, Ierardi E, Burattini O, De Francesco V, Zullo A, Stoppino G, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811–7
   PubMedGoogle Scholar
• Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960–5
   PubMed Web of Science ®Google Scholar
• Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518–32
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–8
   PubMed Web of Science ®Google Scholar
• Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516–26
   PubMed Web of Science ®Google Scholar
• Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006; 66: 249–59
   PubMed Web of Science ®Google Scholar
• Goll R, Olsen T, Cui G, Florholmen J. Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 2006; 7: 107
   PubMed Web of Science ®Google Scholar
• Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum. Cancer Immunol Immunother 2007; 56: 985–95
   PubMed Web of Science ®Google Scholar
• Cui G, Yuan A, Goll R, Olsen T, Husebekk A, Vonen B, et al. Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma–carcinoma sequence. Cancer Immunol Immunother 2007; 56: 1993–2001
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van AG. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007; 56: 453–5
   PubMed Web of Science ®Google Scholar
• Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma mRNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46: 111–23
   PubMedGoogle Scholar
• Moriconi F, Raddatz D, Ho NA, Yeruva S, Dudas J, Ramadori G. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Transl Res 2007; 150: 223–32
   PubMed Web of Science ®Google Scholar
• Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T, Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med 2003; 11: 175–9
   PubMed Web of Science ®Google Scholar
• Kakazu T, Hara J, Matsumoto T, Nakamura S, Oshitani N, Arakawa T, et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am J Gastroenterol 1999; 94: 2149–55
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148–57.
   PubMed Web of Science ®Google Scholar
• Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22–8
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van AG, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226–31
   PubMed Web of Science ®Google Scholar
• De GR, Barbara G. Is irritable bowel syndrome an inflammatory disorder?. Curr Gastroenterol Rep 2008; 10: 385–90
   PubMedGoogle Scholar
• Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468–73
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813–6
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451–9
   PubMed Web of Science ®Google Scholar